Richard D Schulick
Overview
Explore the profile of Richard D Schulick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
300
Citations
18539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishida H, Franklin O, Franco S, Clark T, Stoop T, Kirsch M, et al.
Ann Surg
. 2025 Mar;
PMID: 40047068
Objective: To investigate complications and survival following surgical resection for pancreatic cancer with arterial encasement. Summary Background Data: Surgery for pancreatic cancer with extensive involvement (encasement) of the major visceral...
2.
Sun Z, Torphy R, Miller E, Darehshouri A, Vigil I, Terai T, et al.
bioRxiv
. 2025 Feb;
PMID: 39975353
The lymphatic system plays a central role in lipid absorption, which transports chylomicrons from the small intestine to the circulation. However, the molecular mechanism by which chylomicrons get into the...
3.
Oba A, Tanaka K, Inoue Y, Valente R, Rangelova E, Arnelo U, et al.
Pancreatology
. 2025 Jan;
PMID: 39880760
Background: The effectiveness and preferred reconstruction methods of pancreatectomy associated with vein resection (PAVR) for pancreatic cancer, especially for the extensive portal vein/superior mesenteric vein (PV/SMV) resections (more than 4 ...
4.
Stoop T, Sugawara T, Oba A, Feld I, van Roessel S, van Veldhuisen E, et al.
JAMA Oncol
. 2025 Jan;
PMID: 39847363
Importance: The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy...
5.
Stoop T, Molnar A, Seelen L, Sugawara T, Scheepens J, Ali M, et al.
Ann Surg
. 2025 Jan;
PMID: 39846439
Objective: To investigate whether tangential versus segmental portomesenteric venous resection (PVR) impacts surgical and oncological outcome in patients undergoing pancreatoduodenectomy for pancreatic cancer with portomesenteric vein (PMV) involvement. Summary Background...
6.
Yee E, Torphy R, Thielen O, Easwaran L, Franklin O, Sugawara T, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2877-2878.
PMID: 39833379
No abstract available.
7.
Sun Y, Yee E, Fujiwara Y, Dickinson K, Guo Y, Sun Z, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39805660
Background: Adaptive cellular therapy (ACT), particularly chimeric antigen receptor (CAR)-T cell therapy, has been successful in the treatment of hemopoietic malignancies. However, poor trafficking of administered effector T cells to...
8.
Ishida H, Watanabe S, Franco S, Franklin O, Stoop T, Kirsch M, et al.
Ann Surg
. 2024 Dec;
PMID: 39676646
Objective: To investigate the incidence and risk factors of portomesenteric venous thrombosis (PVT) after pancreatic cancer surgery with portomesenteric venous resection (PVR). Summary Background Data: Pancreatic cancer surgery with PVR...
9.
Hollenbach M, Heise C, Abou-Ali E, Gulla A, Auriemma F, Soares K, et al.
Gut
. 2024 Dec;
74(3):397-409.
PMID: 39642968
Objective: Ampullary neoplastic lesions can be resected by endoscopic papillectomy (EP) or transduodenal surgical ampullectomy (TSA) while pancreaticoduodenectomy is reserved for more advanced lesions. We present the largest retrospective comparative...
10.
Sugawara T, Franco S, Sherman S, Kirsch M, Colborn K, Franklin O, et al.
Pancreatology
. 2024 Nov;
24(8):1340-1347.
PMID: 39609173
Background: Around 5-10 % of pancreatic cancer patients are non-expressors of carbohydrate antigen 19-9 (CA 19-9), which has an unknown impact on the aggressiveness and prognosis of pancreatic adenocarcinoma (PDAC)....